Approximately 50% of people with CF have a chronic bacterial infection caused by the bacterium Pseudomonas aeruginosa from the median age of 5 years. Despite existing antibiotics targeting P. aeruginosa infections, antibiotic resistance poses increasing concern, particularly due to the tendency of P. aeruginosa to produce stable structures called biofilms, as biofilm resistance to conventional antibiotics exceeds that of typical bacterial infections by 10-1,000-fold. Critically in 2018, 17% of P. aeruginosa infections among CF patients were characterized as multi-drug resistant. My project focuses on characterizing the limitations of a promising therapeutic alternative to antibiotic treatment known as phage therapy with the ultimate goal of improving this novel therapeutic.
|Effective start/end date||3/1/21 → 8/31/21|
- Cystic Fibrosis Foundation (BERTUC21H0)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.